← All trials
NCT06389292
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2024
- Primary completion
- May 25, 2028
- Completion date
- Mar 26, 2029
- First posted
- Apr 29, 2024
- Last posted
- Jul 24, 2024
- Enrollment
- 486
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Chinese Academy of Medical SciencesOfficial
- Zhejiang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.